|
M. B. Anciferov
Opening remarks
|
|
|
E.V. Biryukova
Rational Choice Of Pharmacotherapy In Type 2 Diabetes Mellitus
|
13-17 |
|
A.V. Legun, M.S. Vetsheva
Rehydration Therapy And Potentials For Its Control In Patients With Diabetic Coma (literature Review)
|
18-24 |
|
L.A.Ruyatkina, A.V.Lomova, D. S. Ruyatkin
Bone Status In Type 2 Diabetes Mellitus
|
25-31 |
|
A.S.Ametov, B.I.Valitov, N.A.Tchernikova, M. B. Antsiferov
“bolus Advisor”: Effective And Safe Control Of Postprandial Glycemia In Patients On Insulin Pump Therapy
|
32-36 |
|
M. B. Antsiferov, G. Schernthaner, A.S.Ametov
Innovative Hypoglycemic Therapy: A New Strategy For An Old Problem
|
37-47 |
|
A.F.Verbovoy, L.A.Sharonova, N.I.Verbovaya, D. V. Demidova, A.V.Kapishnikov
The Levels Of Vitamin D3 And Parameters Of Bone Metabolism In Women With Type 2 Diabetes Mellitus
|
48-50 |
|
E.E.Arinina, M.A.Rasheed, M. B. Antsiferov
Pharmacoeconomic Analysis Of Advantages Of Combined Incretin Therapy In Patients With Type 2 Diabetes Mellitus By The Example Of Vildagliptin
|
52-57 |
|
A.S.Ametov
Type 2 Diabetes Mellitus And Non-alcoholic Fatty Liver Disease: Guidelines For Endocrinologists
|
58-68 |
|
M.B. Antsiferov, V.S. Pronin
Acromegaly: The Importance Of Assessing The Systemic Manifestations Of The Disease And Their Treatment, Role Of Somatostatin Analogues
|
70-75 |
|
I.V. Guryeva, O. V. Svetlova
Perspective Strategy In The Treatment Of Diabetic Polyneuropathy: The Role Of Antioxidant Therapy
|
76-80 |
|
N.A. Petunina, L.V. Trukhina, E.I. Sinitsina, M.B. Antsiferov
Benefits Of Long-acting Metformin
|
81-84 |
|
I.Yu.Demidova
The Clinical Advantages Of The First Human Glp-1 Analogue Liraglutide In The Treatment Of Patients With Type 2 Diabetes Mellitus
|
86-91 |
|
T. V. Pavlova, E.Yu.Bulanova, D. V. Duplyakov
Amiodarone And Thyroid Dysfunction
|
92-96 |
|
M. V. Shestakova, M. B. Antsiferov, OK Vikulova
Biosimilars: Substitution Problems And Modern Requirements For A Generic Insulin Preparations
|
97-103 |
Русский
